Anavex Life Sciences Corp (AVXL)

[nidan7500]

Xena

We are not dealing with typical symptomatic treatment here, the MOA addresses the root cause of the dysfunction, cellular homeostasis, so I expect benefit to be wide spread.

Agree with this line of reasoning. Since CNS diseases have never been effectively treated (aside from some symptom patches) how do we know the current pass/fail trial metrics are adequate or even how meaningful to the status of the entire CNS? We are doing work that has never been done, we must keep an open mind. Hate to see us pick the wrong turn here.

BTW, the note here about heating water prior to dosing was a very positive example (imo) on the level of detail monitoring and control being applied by AVXL staff. assume nothing. Very well done.

IMO, this recent paper provides some good insights.

https://www.knowablemagazine.org/article/living-world/2020/single-cell-studies?utm_source=twitter&utm_medium=post&utm_campaign=originals&fbclid=IwAR0XhoBZ7XaX5FkuyoTSixFfbRcalytpl0RTtpoz7Z7qdydU09Ozjg0vQ0g

“Cells don’t necessarily care about their history,” Klein says. “They may have to transition to one identity in one place and another identity in another.”